What Do the Trials Say for Catheter Ablation?-What's New in Managing the LAA — An Update on the AMAZE Study (Presenter: David J. Wilber, MD, FHRS, CCDS)

What's New in Managing the LAA — An Update on the AMAZE Study (Presenter: David J. Wilber, MD, FHRS, CCDS)

Video Transcription

Video Summary

Dr. David Wilber provides an update on the AMAZE trial, which focuses on the left atrial appendage and its role in atrial fibrillation (AF). The trial aims to determine the benefit of left atrial appendage isolation using the Lariat device in addition to pulmonary vein isolation for patients with persistent and long-standing persistent AF. The trial is currently ongoing, with 493 patients enrolled and an interim analysis planned for the 500-patient mark. The primary endpoints include freedom from AF and no requirement for new antiarrhythmic drugs. The trial's design also allows for assessment of the safety and effectiveness of left atrial appendage isolation.

Meta Tag

Lecture ID 6481

Location Room 303

Presenter David J. Wilber, MD, FHRS, CCDS

Role Invited Speaker

Session Date and Time May 10, 2019 10:30 AM - 12:00 PM

Session Number S-058

Keywords

Dr. David Wilber

AMAZE trial

left atrial appendage

atrial fibrillation

Lariat device